Gemcitabine (GEM) is a cell-cycle specific inhibitor of DNA synthesis and repair, and has been applied as the first-line therapy for patients with locally advanced or metastatic pancreatic cancers. However, the medi...
详细信息
Gemcitabine (GEM) is a cell-cycle specific inhibitor of DNA synthesis and repair, and has been applied as the first-line therapy for patients with locally advanced or metastatic pancreatic cancers. However, the median survival time is only 5.65 mon when GEM was administrated as a monothearpy. Therefore, novel therapeutic agents and/or combinations with GEM are needed for the treatment of pancreatic cancer. In this study, we aim to evaluate the efficacy of treatment with wbselen (WB), GEM, and combination treatment with GEM and WB in two pancreatic cancer cell lines, JF305 and MiaPaCa-2 cells. The combination index (CI) and the dose-reduction index (DRI) of combined treatment with different dose and time regimes were analyzed based on median-effect theory. Compared with single treatment with GEM, combination treatment displayed decreased response time and IC 50 , and increased maximum inhibition. Among the different combination regimes, the most significant synergistic effect was achieved when the dose ratios of WB to GEM was 2:1 in JF305 cells and 1:1 in MiaPaCa-2 cells after 48 h of drug treatment. When combinations of WB and GEM were used in these two cell lines, the dose of GEM was significantly reduced while the total drug concentration increased, especially after 48 h of drug treatments. Our results indicated that the combination treatment with WB and GEM had synergistic effect against pancreatic cancer in vitro.
Hepatocellular carcinoma (HCC) is one of the major causes of death worldwide. Targeted delivery of drugs to tumor cells can be achieved by introduction of a targeting ligand onto the nanocarrier system. Simultaneous...
详细信息
Hepatocellular carcinoma (HCC) is one of the major causes of death worldwide. Targeted delivery of drugs to tumor cells can be achieved by introduction of a targeting ligand onto the nanocarrier system. Simultaneous delivery of a chemotherapeutic drug and siRNA in one nanocarrier system to the tumor is a promising strategy for cancer treatment. In this study, we prepared cationic liposomes to co-deliver docetaxel (DTX) and small interfering RNA (siRNA). The liposomes were modified by a hepatocellular carcinoma specific homing peptide, SP94. Serum stability assay demonstrated that liposomes can significantly protect the siRNA against enzymatic degradation in serum. The SP94 modified liposomes showed increased cellular uptake and stronger anti-tumor effect compared with the unmodified liposomes on human HCC cells. The data indicated that the SP94 modified liposomes which co-deliver DTX and siRNA could be used for the targeted therapy of hepatocellular carcinoma.
It is a promising treatment strategy to use a nanoparticle-based drug delivery system for cancer patients, which can simultaneously deliver multiple drugs or genes in combination with therapy to induce synergistic eff...
详细信息
It is a promising treatment strategy to use a nanoparticle-based drug delivery system for cancer patients, which can simultaneously deliver multiple drugs or genes in combination with therapy to induce synergistic effects and suppress drug resistance to the tumor. In this study, cationic nanostructured lipid carriers(cNLC) for co-loading anionic small-interfering RNAs(siRNA) and chemotherapeutic docetaxel(DTX) were prepared from different cationic lipids based on particle distribution and loading efficiency. In order to increase the cNLC's positive targeting capacity, a novel peptide SP94 was bound to the surface of cNLC(SP94-cNLC). The cNLC showed good efficiency in loading siRNA and DTX. The SP94-cNLC revealed a better cytotoxicity compared with cNLC and Taxotere?, indicating that SP94 could successfully enhance the internalization capacity of nanoparticles to the liver cancer cells. This new type of cNLC is a potential vehicle when using in co-delivery of chemotherapeutics and siRNAs. The curcumin(CUR)/DTX co-delivery NLC could load both CUR and DTX in high efficiency and showed a sensibilization to DTX chemotherapy. The sensibilization was more obvious when it was used in the aggressive and resistant cancer cells. This CUR/DTX co-delivery system had good potential in treating cancer cells when chemotherapy drug showed little effect alone.
Normally, cellular responses to modified siRNAs or new siRNA delivery systems have been studied in group cell behavior by PCR, western blotting and fluorescence microscopy. In this study, we present a novel high-conte...
详细信息
Normally, cellular responses to modified siRNAs or new siRNA delivery systems have been studied in group cell behavior by PCR, western blotting and fluorescence microscopy. In this study, we present a novel high-content screening (HCS) strategy to evaluate a novel delivery system (named CLD) of siRNA therapeutics, with which both the content of intracellular siRNAs and changes in protein expressing levels have been quantified in group cells and cellular population. We also observed that with the better cell uptake, CLD provided siRNA therapeutics (siBraf) better antitumor capability. This novel strategy was proved to be with efficiency, accuracy and high competency to adherent cell lines, thus making siRNA research more simplified.
暂无评论